What is Vaxxas?
Vaxxas is pioneering a novel approach to vaccine administration with its proprietary high-density microarray patch (HD-MAP) technology. This platform enables needle-free vaccine delivery, targeting immune cells directly beneath the skin. Clinical trials involving over 750 participants have demonstrated the HD-MAP's safety, tolerability, and capacity to elicit robust immune responses across various vaccine modalities, including mRNA, protein subunit, and live attenuated vaccines. The technology's potential to reduce cold-chain requirements and facilitate self-administration positions it as a universal delivery solution with the capacity to disrupt the global vaccine market by enhancing accessibility and reducing costs.
How much funding has Vaxxas raised?
Vaxxas has raised a total of $124.6M across 5 funding rounds:
Series A
$15M
Series B
$20M
Grant
$8.2M
Other Financing Round
$23M
Series D
$58.4M
Series A (2011): $15M, investors not publicly disclosed
Series B (2015): $20M led by Healthcare Ventures, OneVentures, Medical Research Commercialisation Fund (MRCF), and Brandon Capital
Grant (2022): $8.2M supported by Australian Government
Other Financing Round (2022): $23M featuring Uniquest and OneVentures
Series D (2025): $58.4M backed by OneVentures, Brandon Capital, Sprim Global Investments, and LGT Crestone Wealth Management
Key Investors in Vaxxas
OneVentures
OneVentures is a venture capital firm that invests in technology and life science companies. They focus on providing capital and strategic support to businesses with high growth potential, particularly in their early to growth stages. Their investment philosophy centers on backing innovative companies that aim to disrupt established markets or create new ones.
Brandon Capital
Brandon Capital Partners specializes in seed and venture capital investments in the biomedical sector, focusing on life science companies that aim to enhance patient outcomes through innovative medical solutions. They provide support from early-stage seed investment to expansion capital, partnering with entrepreneurs to commercialize their technologies.
Sprim Global Investments
SPRIM Global Investments is a privately held company focusing on investing in companies that enhance R&D capabilities in the life sciences sector. The firm addresses challenges faced by Biotech, Medtech, and CRO companies throughout various clinical stages of drug and device development.
What's next for Vaxxas?
With the recent infusion of $58.4M in a major strategic investment, Vaxxas is well-positioned to transition from development to commercialization. The company's focus will likely shift towards scaling its manufacturing capabilities to meet anticipated market demand and advancing its lead vaccine candidates through regulatory pathways. The enterprise-level funding context suggests Vaxxas is entering a growth phase, aiming to establish its HD-MAP technology as a standard for vaccine delivery globally, potentially expanding its reach into new therapeutic areas and geographical markets.
See full Vaxxas company page
